A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dostarlimab (Primary) ; Niraparib (Primary)
Indications Adrenocortical carcinoma; Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms SCOOP; storytime
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

08 Oct 2024 Planned number of patients changed from 116 to 141.
08 Oct 2024 Planned End Date changed from 12 Apr 2029 to 15 May 2030.
08 Oct 2024 Planned primary completion date changed from 28 Sep 2028 to 29 Oct 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com